摘要
观察木瓜总三萜对葡聚糖硫酸钠(DSS)诱导溃疡性结肠炎小鼠PPARγ/SIRT1/NF-κBp65信号通路及结肠黏膜屏障的影响。将C57BL/6小鼠随机分为正常组、模型组、木瓜总三萜(50,100 mg·kg-1)组和柳氮磺吡啶(250 mg·kg-1)组。实验小鼠通过自由饮用2.5%DSS诱导溃疡性结肠炎(UC)模型,在自由饮用2.5%DSS前3 d,各给药组灌胃给予相应的药物,正常组和模型组给予等体积的0.5%羧甲基纤维素钠溶液,每天1次,连续10 d。每天观察实验小鼠一般状况、记录疾病活动指数(DAI)。末次给药次日,取血,进行血液中TNF-α,IL-1β,IL-6,IFN-γ,IL-4,IL-10含量检测;取结肠进行长度测量、结肠黏膜损伤指数(CMDI)计算、MPO活性检测和组织形态学分析;实时定量PCR法检测结肠组织中E-cadherin,occludin,MUC2,TFF3 mRNA表达,Western blot法检测结肠组织中SIRT1,IKKβ,p-IKKβ,IκBα,p-IκBα及胞浆和胞核中PPARγ,NF-κBp65蛋白表达。结果显示,木瓜总三萜(50,100 mg·kg-1)可显著改善DSS诱导的UC模型小鼠一般状况,降低DAI,CMDI和组织病理学评分,增加结肠长度,减轻结肠黏膜溃疡、糜烂及炎性浸润,恢复黏膜屏障的正常功能,降低血液中促炎因子TNF-α,IL-1β,IL-6,IFN-γ含量,升高抗炎因子IL-4,IL-10含量,抑制结肠组织中MPO活性,上调结肠组织中黏膜屏障保护因子E-cadherin,occludin,MUC2,TFF3 mRNA表达,下调结肠组织胞浆中PPARγ,组织中p-IKKβ,p-IκBα和胞核中NF-κBp65蛋白表达,降低p-IKKβ/IKKβ和p-IκBα/IκBα的比值,上调胞核中PPARγ,组织中SIRT1和胞浆中NF-κBp65蛋白表达(P<0.05或P<0.01),且随着剂量的增加,其作用效果更加明显。表明木瓜总三萜对DSS诱导的小鼠UC有显著治疗作用,其作用机制可能与其调节PPARγ/SIRT1/NF-κBp65信号通路、抑制促炎因子生成、上调肠黏膜屏障保护因子的蛋白表达有关。
To observe the effect of total triterpenoids of Chaenomeles speciosa on PPARγ/SIRT1/NF-κBp65 signaling pathway and intestinal mucosal barrier of ulcerative colitis induced by dextran sulfate sodium(DSS) in mice, C57 BL/6 mice were randomly divided into normal group, model group, total triterpenoids of C. speciosa(50, 100 mg·kg-1) groups and sulfasalazine(250 mg·kg-1) group. The ulcerative colitis(UC) model was induced by orally administering 2.5% DSS to the experimental mice, and the corresponding drugs were given to each group 3 days before the administration with 2.5% DSS. The normal group and the model group were given the equal volume of 0.5% carboxymethyl cellulose sodium solution by gavage continuously for 10 days, q.d. The general conditions of the mice were observed on a daily basis, and the disease activity index(DAI) score was recorded. On the 10 th day after the treatment, mice were put to death, the contents of TNF-α, IL-1β, IL-6, IFN-γ, IL-4 and IL-10 in the blood were detected, colon length was measured, colon mucosa damage index(CMDI) score was calculated, and MPO activity detection and histomorphology analysis were conducted. Real-time PCR was applied to detect the mRNA expressions of E-cadherin, occluding,MUC2 and TFF3;the protein expressions of SIRT1, IKKβ, p-IKKβ, IκBα, p-IκBα and cytosol and nucleus PPARγ, NF-κBp65 in intestinal tissue were detected by western blot. The results indicated that total triterpenoids of C. speciosa(50, 100 mg·kg-1) could significantly improve the general conditions of UC mice, reduce the DAI, CMDI and histopathological scores, increase the colon length, reduce the colonic mucosa ulcers, erosion and inflammatory infiltration, restore the normal intestinal mucosal barrier function, reduce the contents of TNF-α, IL-1β, IL-6, IFN-γ, increase the contents of IL-4 and IL-10 in the blood, inhibit MPO activity in colon tissue, up-regulate the mRNA expressions of E-cadherin, occludin, MUC2 and TFF3 in colon tissue, down-regulate the protein expressions of cytosol PPARγ, tissue p-IKKβ, p-IκBα and nucleus NF-κBp65 in the colon tissue, decrease the p-IKKβ/IKKβ and p-IκBα/IκBα ratios, up-regulate the protein expressions of nucleus PPARγ, tissue SIRT1 and cytosol NF-κBp65(P<0.05 or P<0.01, respectively), with a dose-effect relationship between the total triterpenoids of C. speciosa treated groups. These findings suggested that total triterpenoids of C. speciosa had a significantly therapeutic effect on UC mice induced by DSS, its mechanism might be related to the regulation of PPARγ/SIRT1/NF-κBp65 signaling pathway, the inhibition of pro-inflammatory factor formation and the up-regulation of protein expression of protective factors.
作者
熊兴军
李小妹
何毓敏
李小琴
许海燕
冯旻璐
贺海波
张继红
朱姝
小松佳子
邹坤
XIONG Xing-jun;LI Xiao-mei;HE Yu-min;LI Xiao-qin;XU Hai-yan;FENG Min-lu;HE Hai-bol;ZHANG Ji-hong;ZHU Shu;KOMATSU Katsuko;ZOU Kun(College of Biological and Pharmaceutical Sciences,China Three Gorges University,Yichang 443002,China;Changyang Hospital of Traditional Chinese Medicine,Changyang 443001,China;Traditional Chinese Medicine Hospital of China Three Gorges University &Yichang Hospital of Traditional Chinese Medicine,Yichang 443002,China Division of Pharmacognosy,Institute of Natural Medicine,University of Toyama,Toyama 930-0194,Japan)
出处
《中国中药杂志》
CAS
CSCD
北大核心
2018年第21期4295-4304,共10页
China Journal of Chinese Materia Medica
基金
三峡大学硕士学位论文培优基金项目(2017YPY086,2018SSPY140)
湖北省民间药物现代工程研究技术中心项目(2015ZY007)
